Alias
科研级 Efungumab ( 依芬古单抗 ), Anti-HSP91 Homolog Recombinant Antibody, Research Grade Efungumab
Applications
FC, IP, ELISA, Neut, FuncS, IF, WB
Purity
≥95% as determined by SDS-PAGE
Buffer
Supplied in PBS, PH7.5
Target
HSP91 homolog[Candida albicans]
Sequence
Please contact our sales representative to learn more information about this reagents.
Background
Efungumab (trade name Mycograb) was a drug developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat candidemia (a bloodstream infection caused by pathogenic yeast) in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.
Storage
该产品可在 2°C-8°C 下保存一个月,活性不会明显降低。在 -20°C 至 -80°C 下保存,可稳定保存十二个月。避免反复冻融,用冰袋运输。